OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC

Sotorasib monotherapy has demonstrated a durable objective response rate (ORR) of 41%, and 33% 2-year overall survival (OS) in advanced pre-treated KRAS p.G12C-mutated NSCLC. In preclinical studies, sotorasib combined with anti-PD-1 therapy increased CD8+ T-cell infiltration and enhanced anti-tumor efficacy. Here we provide the first assessment of safety and efficacy of sotorasib with either pembrolizumab (Pembro) or atezolizumab (Atezo) anti-PD-(L)1 immunotherapy (IO) from CodeBreaK 100/101 phase 1b dose exploration.